Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 24Myeloid 11Lymphoid 7Thoracic 4Other solid neoplasm 4Classical hematology 3Gastrointestinal 2Dermatologic 2Sarcoma 1Plasma cell 1Other neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1CNS 1Breast 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 38Radiotherapy 35Magnetic Resonance Spectroscopy 32Specimen Handling 22Cetuximab 18Fluorouracil 17Radiotherapy, Intensity-Modulated 16Platinum 161,2-diaminocyclohexaneplatinum II citrate 16Biopsy 15Paclitaxel 13Carboplatin 13Nivolumab 11Docetaxel 10pembrolizumab 8Radiation 8Fluorodeoxyglucose F18 8Erlotinib Hydrochloride 8Bortezomib 8Bevacizumab 8Gemcitabine 7Sorafenib 6Immunoglobulin G 6Disulfides 6aldesleukin 5Hydroxyurea 5Gefitinib 5Chemotherapy, Adjuvant 5(225)Ac-DOTA-c(RGDyK) 5cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Decitabine × Head & Neck × Clear all
NCT00085293 2018-11-29

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 4 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡